HCA Healthcare (NYSE:HCA) Given New $268.00 Price Target at Citigroup

HCA Healthcare (NYSE:HCA) had its target price increased by Citigroup from $215.00 to $268.00 in a research note published on Wednesday, The Fly reports. The firm currently has a neutral rating on the stock.

Other analysts have also recently issued reports about the company. BMO Capital Markets increased their price target on HCA Healthcare from $200.00 to $222.00 and gave the stock a market perform rating in a research report on Monday, April 26th. began coverage on HCA Healthcare in a report on Thursday, May 13th. They issued a neutral rating and a $215.00 price objective for the company. Truist Securities increased their price target on HCA Healthcare from $200.00 to $230.00 and gave the company a buy rating in a research note on Wednesday, April 14th. Seaport Res Ptn reaffirmed a buy rating on shares of HCA Healthcare in a research note on Friday, July 9th. Finally, Raymond James restated an outperform rating and issued a $225.00 target price (up previously from $190.00) on shares of HCA Healthcare in a report on Thursday, April 29th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $231.48.

Shares of NYSE HCA opened at $249.25 on Wednesday. The company’s 50 day moving average price is $212.68. HCA Healthcare has a 52-week low of $114.38 and a 52-week high of $254.45. The firm has a market capitalization of $82.41 billion, a PE ratio of 17.10, a P/E/G ratio of 1.21 and a beta of 1.63. The company has a debt-to-equity ratio of 18.06, a current ratio of 1.45 and a quick ratio of 1.15.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Monday, July 19th. The company reported $4.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.16 by $1.21. The firm had revenue of $14.44 billion for the quarter, compared to analysts’ expectations of $13.61 billion. HCA Healthcare had a return on equity of 234.29% and a net margin of 8.87%. HCA Healthcare’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.23 earnings per share. As a group, research analysts anticipate that HCA Healthcare will post 16.7 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 30th. Investors of record on Thursday, September 16th will be issued a dividend of $0.48 per share. The ex-dividend date of this dividend is Wednesday, September 15th. This represents a $1.92 annualized dividend and a dividend yield of 0.77%. HCA Healthcare’s dividend payout ratio is 16.54%.

In other HCA Healthcare news, SVP Deborah M. Reiner sold 3,432 shares of the firm’s stock in a transaction dated Tuesday, May 11th. The stock was sold at an average price of $208.33, for a total transaction of $714,988.56. Following the transaction, the senior vice president now directly owns 6,576 shares in the company, valued at $1,369,978.08. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider A Bruce Moore, Jr. sold 12,000 shares of the firm’s stock in a transaction dated Monday, May 3rd. The shares were sold at an average price of $205.32, for a total value of $2,463,840.00. Following the transaction, the insider now owns 102,381 shares in the company, valued at $21,020,866.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 342,446 shares of company stock valued at $68,773,585. 1.60% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S grew its position in shares of HCA Healthcare by 113.3% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 22,099 shares of the company’s stock valued at $4,162,000 after purchasing an additional 11,738 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in HCA Healthcare by 3.0% during the first quarter. Oppenheimer & Co. Inc. now owns 20,385 shares of the company’s stock worth $3,839,000 after buying an additional 589 shares in the last quarter. Park National Corp OH bought a new position in HCA Healthcare during the first quarter worth about $2,021,000. Tiger Eye Capital LLC bought a new position in HCA Healthcare during the first quarter worth about $11,772,000. Finally, Baird Financial Group Inc. lifted its stake in HCA Healthcare by 3.4% during the first quarter. Baird Financial Group Inc. now owns 30,812 shares of the company’s stock worth $5,803,000 after purchasing an additional 1,005 shares during the period. 68.68% of the stock is currently owned by institutional investors.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

See Also: Quiet Period Expirations Explained

The Fly logo

Analyst Recommendations for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.